{"id":488,"date":"2026-07-07T03:32:40","date_gmt":"2026-07-07T03:32:40","guid":{"rendered":"https:\/\/mrna.creative-biolabs.com\/blog\/?p=488"},"modified":"2026-07-07T03:32:40","modified_gmt":"2026-07-07T03:32:40","slug":"hybrid-vectors-and-virus-like-particles-for-mrna-delivery","status":"publish","type":"post","link":"https:\/\/mrna.creative-biolabs.com\/blog\/hybrid-vectors-and-virus-like-particles-for-mrna-delivery\/","title":{"rendered":"Hybrid Vectors and Virus-Like Particles for mRNA Delivery"},"content":{"rendered":"

Discover how hybrid vectors, lipopolyplexes, and virus-like particles overcome stability and targeting barriers for mRNA delivery in preclinical research.<\/em><\/span><\/p>\n

Introduction<\/span><\/h2>\n

Messenger RNA (mRNA)-based therapeutics have transformed the landscape of vaccine development, gene replacement therapy, and cancer immunotherapy. The clinical success of mRNA vaccines has validated this modality as a versatile platform capable of rapid design and production. However, the therapeutic potential of mRNA is fundamentally limited by the challenge of efficient delivery. Naked mRNA is inherently unstable in biological fluids, susceptible to rapid degradation by serum ribonucleases, and unable to cross the negatively charged cell membrane on its own. A robust, safe, and targetable delivery system is therefore not merely advantageous but essential for translating mRNA-based candidates from concept to clinic.<\/span><\/p>\n

While lipid nanoparticles (LNPs) have served as the workhorse delivery platform for the first generation of mRNA products, their limitations in endosomal escape efficiency, targeting specificity, and cargo compatibility have driven the search for next-generation alternatives. This article examines emerging delivery platforms including Hybrid Vector<\/a><\/span><\/strong> systems, Lipopolyplex<\/a><\/span><\/strong> formulations, Cationic Nanoemulsion<\/a><\/span><\/strong> technologies, and Enveloped Virus-Like Particle<\/a><\/span><\/strong> platforms. These advanced systems address key bottlenecks in stability, cytosolic release, and tissue-specific targeting, offering researchers new tools for challenging preclinical programs.<\/span><\/p>\n

\"\"<\/p>\n

The mRNA Delivery Challenge: Barriers and Requirements<\/span><\/h2>\n

For mRNA to reach the ribosome and produce functional protein, a delivery vector must successfully navigate multiple biological barriers. First, it must protect the fragile nucleic acid cargo from enzymatic degradation in the extracellular environment. Upon reaching target cells, the vector must facilitate cellular internalization, typically through receptor-mediated or adsorptive endocytosis. The most critical bottleneck, however, is endosomal escape. A large proportion of internalized mRNA is trafficked through the endolysosomal pathway, where the acidic and enzyme-rich environment rapidly degrades the payload before it reaches the cytoplasm. Vectors capable of efficient endosomal disruption can dramatically increase the fraction of mRNA that becomes translationally active.<\/span><\/p>\n

Beyond these core functions, ideal mRNA carriers should demonstrate minimal off-target accumulation, controllable immunogenicity profiles, and compatibility with scalable manufacturing processes. These requirements have prompted the development of platforms that integrate functional elements from multiple materials, giving rise to hybrid and virus-inspired delivery systems. Polymer-lipid hybrid nanostructures represent one of the most promising frontiers in mRNA delivery research, combining the transfection efficiency of lipids with the structural tunability of polymers.<\/span><\/p>\n

Hybrid Vector Platforms: Architecture and Mechanisms<\/span><\/h2>\n

The concept of a Hybrid Vector<\/a> <\/span><\/strong>is rooted in the idea that no single material class can optimally address all delivery barriers. By integrating lipids, polymers, peptides, or inorganic nanomaterials into a unified architecture, hybrid vectors achieve functional synergies that are difficult to realize with homogeneous formulations.<\/span><\/p>\n

Hybrid vectors typically adopt a core-shell nanostructure. The core provides nucleic acid condensation and protection, while the shell mediates interactions with the biological environment. This modular design allows independent optimization of each functional layer. For instance, a pH-responsive polymer core can be engineered to undergo conformational changes that disrupt the endosomal membrane upon acidification, while a biocompatible lipid shell can be functionalized with targeting ligands such as peptides or aptamers for tissue-specific homing. Compared to standard LNPs, which rely primarily on ionizable lipid components for endosomal destabilization, hybrid systems can incorporate dedicated endosomolytic modules, resulting in endosomal escape efficiencies that are both higher and more predictable across diverse cell types.<\/span><\/p>\n

A recent study by Mazrad and colleagues (2025) demonstrated that lipid-polyhydroxyalkanoate (PHA) hybrid nanoparticles achieve robust transfection while maintaining excellent colloidal stability, highlighting the potential of combining biodegradable polyesters with lipid components for sustainable mRNA delivery platforms.<\/span><\/p>\n

Lipopolyplex: Precision Co-Delivery with a Core-Shell Design<\/span><\/h2>\n

The Lipopolyplex<\/span><\/strong><\/a> represents a specific and highly refined class of hybrid vector. Structurally, it consists of a condensed polyplex core, where cationic polymers compact the mRNA payload, surrounded by a lipid bilayer shell. This ternary architecture offers several distinct advantages. The polymer core, often composed of biodegradable materials such as poly(beta-amino ester) (PBAE), not only protects the mRNA from nuclease attack but also serves as the primary engine for endosomal escape through the proton sponge effect. Upon endosomal acidification, the buffering capacity of the polymer triggers an osmotic influx of protons and chloride ions, leading to vesicle rupture and cytosolic release of the nucleic acid cargo.<\/span><\/p>\n

A defining feature of the Lipopolyplex<\/span><\/strong><\/a> platform is its capacity for stoichiometric co-delivery. Because the polymer core can simultaneously condense multiple nucleic acid species at precisely controlled charge ratios, a single Lipopolyplex particle can deliver two distinct therapeutic payloads \u2014 such as an antigen-encoding mRNA and an immune adjuvant-encoding plasmid \u2014 to the same target cell in a defined ratio. This capability is particularly valuable in personalized cancer vaccine applications, where co-delivery of tumor neoantigen mRNA alongside immunomodulatory factors can significantly enhance the breadth and magnitude of T-cell responses.<\/span><\/p>\n

Fan et al.<\/em> (2024) demonstrated in a study published in Science Advances<\/em> that a Lipopolyplex-formulated mRNA cancer vaccine elicited potent neoantigen-specific T-cell responses and robust antitumor activity in vivo<\/em>, underscoring the translational potential of this delivery platform for cancer immunotherapy.<\/span><\/p>\n

Cationic Nanoemulsion: Stability and Scalability in a Single Platform<\/span><\/h2>\n

While many advanced delivery systems sacrifice manufacturability for performance, the Cationic Nanoemulsion<\/a><\/span><\/strong> platform strikes a deliberate balance between biological efficacy and industrial feasibility. A cationic nanoemulsion is an oil-in-water emulsion stabilized by cationic lipids such as DOTAP. The oil core provides a thermodynamically favorable environment for incorporating hydrophobic components, while the cationic surface interacts electrostatically with negatively charged mRNA, achieving efficient condensation and protection.<\/span><\/p>\n

Unlike the complex microfluidic processes required for LNP production, Cationic Nanoemulsion<\/a><\/span><\/strong> formulations can be manufactured using straightforward probe sonication methods that translate readily to pilot and commercial scales. This reduces anticipated cost of goods and streamlines technology transfer to manufacturing partners. The emulsion architecture also confers superior storage stability compared to many LNP formulations, an important consideration for programs targeting global distribution.<\/span><\/p>\n

The Cationic Nanoemulsion<\/a><\/span><\/strong> platform is particularly well-suited for self-amplifying RNA (saRNA) delivery. The inherently larger size of saRNA constructs, which encode viral replicase machinery in addition to the therapeutic gene, demands a delivery vehicle with sufficient loading capacity and structural flexibility. The liquid core of the nanoemulsion accommodates these larger payloads without the packing constraints that can limit encapsulation in rigid lipid structures. Furthermore, the cationic surface charge can be fine-tuned within a therapeutic window that balances efficient cellular uptake against the risk of systemic toxicity, and additional targeting ligands can be conjugated to the emulsion surface for cell-specific delivery to antigen-presenting cells or other populations of interest.<\/span><\/p>\n

Enveloped Virus-Like Particles: Harnessing Viral Machinery Without Replication Risk<\/span><\/h2>\n

The Enveloped Virus-Like Particle<\/a> <\/span><\/strong>represents a fundamentally different design philosophy. Rather than assembling carriers from synthetic materials, eVLPs co-opt the self-assembly machinery of viruses to produce non-replicative, non-infectious nanoparticles that retain the cell-entry capabilities of their parental viruses. Because eVLPs are devoid of viral genetic material and designed to be replication-incompetent, they offer a safety profile suitable for repeated administration while maintaining the high transduction efficiency characteristic of viral vectors.<\/span><\/p>\n

The defining mechanistic advantage of eVLPs lies in their membrane fusion capability. Unlike lipid-based carriers that rely on stochastic endosomal disruption, many eVLPs possess envelope glycoproteins that catalyze direct fusion with cellular or endosomal membranes. This fusion-mediated entry bypasses the endosomal degradation pathway, achieving highly efficient cytosolic release of mRNA payloads. By engineering the envelope proteins, researchers can also control cellular tropism, directing eVLPs to specific tissues or cell populations with a degree of selectivity difficult to achieve with passive targeting approaches. A review by Berreiros-Hortala et al.<\/em> (2024) in the International Journal of Molecular Sciences<\/em> highlighted the growing diversity of VLP platforms and their expanding applications in allergen-specific immunotherapy and vaccine development.<\/span><\/p>\n

Different viral scaffolds offer distinct biological signatures that can be matched to specific therapeutic goals. The three eVLP platforms described below illustrate this diversity of application.<\/span><\/p>\n

Lentivirus-Like Particles: Transient Delivery for Gene Editing and Cell Engineering<\/span><\/h2>\n

The Lentivirus-Like Particle<\/span><\/strong><\/a>, or LVLP, is engineered from lentiviral structural components with critical enzymatic functions deliberately removed. By excluding the viral reverse transcriptase and integrase (Pol), LVLPs deliver mRNA or ribonucleoprotein (RNP) cargos that remain confined to the cytoplasm. The mRNA is translated transiently into functional protein, and any delivered genome editing machinery acts without risk of permanent genomic integration. This non-integrating, transient expression profile is particularly valuable for applications where permanent genetic modification is undesirable, such as cell reprogramming with transcription factors or therapeutic genome editing where the editing nuclease machinery needs to be present only briefly.<\/span><\/p>\n

LVLPs retain the large packaging capacity of their lentiviral precursors, accommodating cargo constructs exceeding 10,000 nucleotides. Their ability to be pseudotyped with diverse envelope glycoproteins, such as VSV-G or cell-type-specific ligands, enables transduction of a remarkably broad range of target cells, including non-dividing primary cells, hematopoietic stem cells, and neuronal populations. For researchers developing cell therapies or performing functional genomic screens in difficult-to-transfect primary cells, the Lentivirus-Like Particle<\/a><\/span><\/strong> platform provides a non-integrating alternative that bridges the gap between high transduction efficiency and the stringent safety requirements of clinical-grade products.<\/span><\/p>\n

Murine Leukaemia Virus-Like Particles: A Well-Characterized Scaffold for Targeted Delivery<\/span><\/h2>\n

The Murine Leukaemia Virus-Like Particle<\/a><\/span><\/strong>, or MLVLP, is built upon the extensively characterized Gag protein core of murine leukemia virus. This well-studied scaffold undergoes robust self-assembly and budding, enabling high-yield production with simplified process optimization. The Gag core retains the native membrane fusion and intracellular uncoating mechanisms that permit efficient endosomal escape and cytosolic cargo release following endocytic uptake.<\/span><\/p>\n

A distinctive feature of the MLVLP platform is its compatibility with RNA aptamer-based cargo loading systems. Therapeutic mRNA can be engineered to contain specific RNA aptamer sequences, such as the MS2 stem-loop, which are recognized with high affinity by cognate aptamer-binding proteins co-expressed during particle assembly. This selective packaging mechanism maximizes cargo loading efficiency and ensures that only the intended mRNA payload is incorporated into the final VLP product. The resulting particles can deliver mRNA, small interfering RNA, or even functional proteins to target cells, with customized envelope engineering enabling receptor-specific targeting. For applications including targeted oncology \u2014 where cytotoxic payloads must be delivered exclusively to malignant cells \u2014 and next-generation mRNA vaccines requiring efficient antigen-presenting cell transduction, the Murine Leukaemia Virus-Like Particle<\/a><\/span><\/strong> platform offers a versatile and well-characterized delivery solution.<\/span><\/p>\n

Venezuelan Equine Encephalitis Virus-Like Particles: Self-Amplifying RNA for Potent Immunization<\/span><\/h2>\n

The Venezuelan Equine Encephalitis Virus-Like Particle<\/span><\/strong><\/a>, or VEEVLP, is derived from an alphavirus scaffold and is uniquely optimized for the delivery of self-amplifying RNA. Unlike conventional mRNA, saRNA encodes not only the therapeutic gene of interest but also the viral replicase machinery \u2014 specifically, the non-structural proteins nsp1-4 that form an RNA-dependent RNA polymerase (RdRp) complex. Upon cytosolic delivery, the RdRp complex amplifies the saRNA into hundreds to thousands of copies, driving sustained, high-level expression of the encoded protein from an exceptionally low input dose.<\/span><\/p>\n

This self-amplifying property gives the Venezuelan Equine Encephalitis Virus-Like Particle<\/a><\/span><\/strong> platform a compelling potency advantage. Where one conventional LNP delivers one mRNA molecule to one cell, a single VEEVLP-saRNA particle can initiate an intracellular amplification cascade that produces therapeutic protein levels comparable to those achieved by orders of magnitude more conventional mRNA. The system also features an intrinsic adjuvant effect: the cytoplasmic replication process activates innate immune sensing pathways, generating a local inflammatory context that enhances antigen-specific adaptive immune responses \u2014 a feature particularly beneficial for vaccine applications. A study by Rice et al.<\/em> (2022) published in Frontiers in Immunology<\/em> demonstrated that an saRNA vaccine utilizing a VEEV replicon backbone elicited robust cellular immunogenicity and cross-variant neutralizing antibodies against SARS-CoV-2, highlighting the clinical relevance of this approach.<\/span><\/p>\n

The VEEVLP production system uses a split-helper design in which the structural genes required for particle assembly are supplied in trans<\/em> on separate plasmids, ensuring that the final product is strictly replication-defective. The saRNA replication cycle is confined to the cytoplasm, eliminating any risk of genomic integration, and the particles are incapable of producing infectious progeny. This combination of potent expression, built-in immunostimulation, and stringent safety engineering makes VEEVLPs an attractive platform for infectious disease vaccines and therapeutic cancer vaccines alike.<\/span><\/p>\n

Practical Considerations for Preclinical mRNA Delivery Programs<\/span><\/h2>\n

Selecting the appropriate delivery platform for a given mRNA therapeutic program requires balancing multiple interdependent factors. Researchers must consider several key parameters during the preclinical design phase.<\/span><\/p>\n

Cargo characteristics are a primary determinant of platform suitability. The size and structural complexity of the nucleic acid payload \u2014 whether it is a standard mRNA transcript, a large self-amplifying RNA, or a multi-component RNP complex \u2014 will influence which delivery architectures can accommodate it effectively. For saRNA programs requiring large cargo capacity and high-level expression from low doses, the VEEVLP or cationic nanoemulsion platforms merit strong consideration. For applications demanding precise stoichiometric co-delivery of two distinct nucleic acid species, the lipopolyplex platform offers unmatched control. For programs where transient, non-integrating delivery to difficult-to-transfect primary cells is paramount, LVLPs provide an optimal balance of efficiency and safety.<\/span><\/p>\n

Target cell and tissue tropism is equally important. The choice of delivery platform, envelope pseudotype, and surface functionalization strategy must be aligned with the intended target cell population. Dendritic cell targeting for vaccine applications, hepatocyte targeting for metabolic protein replacement, and tumor-selective delivery for oncolytic approaches each impose distinct requirements on vector design. For researchers developing programs that involve repeated administration, the immunogenicity profile of the delivery vehicle must also be carefully evaluated, as anti-vector immune responses can limit the efficacy of subsequent doses.<\/span><\/p>\n

Scalability from research-grade production to compliant manufacturing should be considered early in the development timeline. Platforms with inherently scalable manufacturing processes \u2014 such as cationic nanoemulsions produced by sonication or VLPs produced in established bioreactor systems \u2014 can reduce the technical risk and timeline associated with later-stage process transfer. Creative Biolabs supports research teams through tailored preclinical CRO services that address each of these decision points, from initial platform selection and formulation optimization through in vitro<\/em> characterization and in vivo<\/em> efficacy evaluation. Every project benefits from a customized experimental design that reflects the specific biological requirements of the target indication and the practical constraints of the development pathway.<\/span><\/p>\n

Conclusion<\/span><\/h2>\n

The next generation of mRNA delivery platforms is defined by architectural sophistication and functional modularity. Hybrid vectors, lipopolyplexes, cationic nanoemulsions, and virus-like particles each offer distinct advantages over conventional LNP-based approaches, addressing long-standing challenges in endosomal escape, targeted delivery, co-delivery precision, and manufacturing scalability. Whether the goal is to elicit potent antitumor immunity, achieve transient therapeutic protein expression, or enable safe genome editing in primary cells, matching the delivery platform to the biological requirements of the application is an essential step in preclinical development.<\/span><\/p>\n

For research teams navigating this expanding landscape of delivery technologies, partnering with an experienced preclinical CRO can accelerate decision-making and reduce technical risk. Creative Biolabs offers comprehensive mRNA delivery development services spanning hybrid vector engineering, lipopolyplex formulation, cationic nanoemulsion optimization, and virus-like particle design and production. To discuss how these platforms can be tailored to your specific therapeutic program, contact our scientific team to explore customized solutions for your preclinical research needs.<\/span><\/p>\n

FAQ<\/span><\/h2>\n

Q: What are the main differences between hybrid vectors and conventional lipid nanoparticles for mRNA delivery?<\/strong><\/span><\/p>\n

A: Hybrid vectors integrate multiple material classes \u2014 such as lipids with polymers, peptides, or inorganic nanomaterials \u2014 into a unified core-shell architecture. This modular design allows independent optimization of nucleic acid condensation, endosomal escape, and surface targeting. Conventional LNPs rely primarily on ionizable lipid components for all these functions, which can limit their efficiency and tunability. Hybrid vectors can incorporate dedicated pH-responsive polymers for more robust endosomal disruption and attach targeting ligands more readily to their outer shell.<\/span><\/p>\n

Q: Why are virus-like particles considered safer than viral vectors for mRNA delivery?<\/strong><\/span><\/p>\n

A: Virus-like particles (VLPs) are engineered to be non-replicative and non-infectious. They are produced by expressing only the structural proteins of a virus, without including the viral genome or the enzymatic machinery required for replication. This means VLPs can enter target cells and release their mRNA cargo but cannot produce new infectious particles or integrate into the host genome. This design eliminates the insertional mutagenesis and pathogenic risks associated with replication-competent viral vectors.<\/span><\/p>\n

Q: What makes lipopolyplex particularly suitable for cancer vaccine development?<\/strong><\/span><\/p>\n

A: The lipopolyplex platform excels at stoichiometric co-delivery \u2014 the ability to package two distinct nucleic acid payloads, such as an antigen-encoding mRNA and an adjuvant-encoding plasmid, into the same particle at a precisely controlled ratio. This ensures that antigen-presenting cells receive the optimal combination of antigen and immune-stimulatory signals simultaneously, which is critical for priming effective antitumor T-cell responses. The polymer core also provides efficient endosomal escape through the proton sponge effect, maximizing translation of the delivered mRNA.<\/span><\/p>\n

Q: How are self-amplifying RNA (saRNA) delivery systems different from conventional mRNA delivery?<\/strong><\/span><\/p>\n

A: saRNA constructs are significantly larger than conventional mRNA because they encode viral replicase proteins in addition to the therapeutic gene. This imposes greater demands on the delivery vehicle in terms of cargo capacity and structural flexibility. Platforms such as VEEVLPs and cationic nanoemulsions are particularly well-suited for saRNA delivery because their architectures can accommodate large nucleic acid payloads. Once delivered, the saRNA self-amplifies in the cytoplasm, yielding therapeutic protein levels from much lower initial doses compared to non-amplifying mRNA.<\/span><\/p>\n

Q: How can partnering with a preclinical CRO support mRNA delivery platform development?<\/strong><\/span><\/p>\n

A: A preclinical CRO with expertise in mRNA delivery can help research teams navigate platform selection, formulation optimization, and preclinical characterization. Services may include in silico<\/em> vector design, polymer and lipid synthesis, nanoparticle assembly and physicochemical characterization, in vitro<\/em> transfection and cytotoxicity testing, and in vivo<\/em> biodistribution and efficacy studies. This integrated support allows academic laboratories and biotech companies to access specialized expertise and infrastructure without the need for in-house investment, potentially accelerating the transition from concept to lead candidate.<\/span><\/p>\n

References<\/span><\/h2>\n

1.Fan T, et al.<\/em>. “Lipopolyplex-formulated mRNA cancer vaccine elicits strong neoantigen-specific T cell responses and antitumor activity.” Science Advances<\/em>. 2024;10(41):eadn9961. DOI: 10.1126\/sciadv.adn9961<\/a><\/span><\/p>\n

2.Mazrad ZAI, et al.<\/em>. “Lipid-polyhydroxyalkanoate hybrid nanoparticles as sustainable drug delivery platform for mRNA.” European Journal of Pharmaceutics and Biopharmaceutics<\/em>. 2025;114755. DOI: 10.1016\/j.ejpb.2025.114755<\/a><\/span><\/p>\n

3.Rice A, et al.<\/em>. “Heterologous saRNA prime, DNA dual-antigen boost SARS-CoV-2 vaccination elicits robust cellular immunogenicity and cross-variant neutralizing antibodies.” Frontiers in Immunology<\/em>. 2022;13:910136. DOI: 10.3389\/fimmu.2022.910136<\/a><\/span><\/p>\n

4.Berreiros-Hortala H, et al.<\/em>. “Virus-like Particles as Vaccines for Allergen-Specific Therapy: An Overview of Current Developments.” International Journal of Molecular Sciences<\/em>. 2024;25(13):7429. DOI: 10.3390\/ijms25137429<\/a><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

Discover how hybrid vectors, lipopolyplexes, and virus-like particles overcome stability and targeting barriers for mRNA delivery in preclinical research. Introduction Messenger RNA (mRNA)-based therapeutics have transformed the landscape of vaccine development, geneRead More…<\/a><\/p>\n","protected":false},"author":1,"featured_media":490,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[79,7,80],"_links":{"self":[{"href":"https:\/\/mrna.creative-biolabs.com\/blog\/wp-json\/wp\/v2\/posts\/488"}],"collection":[{"href":"https:\/\/mrna.creative-biolabs.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mrna.creative-biolabs.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mrna.creative-biolabs.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mrna.creative-biolabs.com\/blog\/wp-json\/wp\/v2\/comments?post=488"}],"version-history":[{"count":1,"href":"https:\/\/mrna.creative-biolabs.com\/blog\/wp-json\/wp\/v2\/posts\/488\/revisions"}],"predecessor-version":[{"id":491,"href":"https:\/\/mrna.creative-biolabs.com\/blog\/wp-json\/wp\/v2\/posts\/488\/revisions\/491"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mrna.creative-biolabs.com\/blog\/wp-json\/wp\/v2\/media\/490"}],"wp:attachment":[{"href":"https:\/\/mrna.creative-biolabs.com\/blog\/wp-json\/wp\/v2\/media?parent=488"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mrna.creative-biolabs.com\/blog\/wp-json\/wp\/v2\/categories?post=488"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mrna.creative-biolabs.com\/blog\/wp-json\/wp\/v2\/tags?post=488"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}